The Supreme Court's decision to reject Prometheus Labs' (NSRGY.PK) testing patents has wider...

|By:, SA News Editor

The Supreme Court's decision to reject Prometheus Labs' (NSRGY.PK) testing patents has wider industry implications and could be a setback for other biotechs that sell diagnostic devices, including Roche (RHHBY.PK), Abbot (ABT +0.3%) and Myriad Genetics (MYGN -5.4%)